We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
+37.47%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$343M
AUM Growth
+$44.3M
Cap. Flow
-$16.9M
Cap. Flow %
-4.94%
Top 10 Hldgs %
36.95%
Holding
100
New
31
Increased
17
Reduced
28
Closed
22

Top Buys

Rank Stock Value
1
SOLY
Soliton, Inc.
SOLY
+$10.1M
2
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$9.42M
3
GLD icon
SPDR Gold Trust
GLD
+$9.03M
4
RCM
R1 RCM Inc. Common Stock
RCM
+$7.85M
5
COR icon
Cencora
COR
+$7.79M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$21.5M
2
NVST icon
Envista
NVST
+$12.8M
3
BSX icon
Boston Scientific
BSX
+$10.2M
4
AGN
Allergan plc
AGN
+$9.74M
5
BIIB icon
Biogen
BIIB
+$8.46M

Sector Composition

Rank Sector Weight
1 Healthcare 76.03%
2 Industrials 2.48%
3 Financials 0.92%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VKTX icon
26
Viking Therapeutics
VKTX
$3.8B
$5.12M 1.49%
709,780
-42,461
-6% -$282K
RDUS
27
DELISTED
Radius Health, Inc.
RDUS
$4.94M 1.44%
362,402
-25,000
-6% -$344K
CVM icon
28
PUT
CEL-SCI Corp
CVM
$21.8M
$4.94M 1.44%
11,030
-32,407
-75% -$13.3M
AFMD
29
DELISTED
Affimed
AFMD
$4.31M 1.26%
93,315
-8,505
-8% -$237K
CHAQ.U
30
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
$4.2M 1.23%
+400,000
New +$4.02M
ARDX icon
31
Ardelyx
ARDX
$1.23B
$4.16M 1.21%
601,534
-20,000
-3% -$139K
LRMR icon
32
Larimar Therapeutics
LRMR
$413M
$4.09M 1.19%
318,258
+123,911
+64% +$1.44M
QTRX icon
33
Quanterix
QTRX
$175M
$4M 1.17%
145,907
-91,174
-38% -$2.3M
BSX icon
34
Boston Scientific
BSX
$72B
$3.93M 1.15%
112,036
-283,711
-72% -$10.2M
IMVT icon
35
Immunovant
IMVT
$7.91B
$3.71M 1.08%
152,450
+38,317
+34% +$821K
BIIB icon
36
Biogen
BIIB
$29.8B
$3.69M 1.08%
13,800
-28,138
-67% -$8.46M
BIIB icon
37
PUT
Biogen
BIIB
$29.8B
$3.69M 1.08%
+13,800
New +$4.15M
NBP
38
NovaBridge Biosciences American Depositary Shares
NBP
$186M
$3.54M 1.03%
118,409
-354,266
-75% -$7.33M
ESPR
39
DELISTED
Esperion Therapeutics
ESPR
$3.16M 0.92%
61,600
-19,000
-24% -$795K
CYPH
40
Cypherpunk Technologies Inc
CYPH
$67.8M
$3.14M 0.92%
150,200
+40,246
+37% +$863K
VAPO
41
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$3.11M 0.91%
+9,494
New +$2M
SYRS
42
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.91M 0.85%
27,290
-19,563
-42% -$1.76M
VRAY
43
DELISTED
ViewRay, Inc.
VRAY
$2.9M 0.85%
+1,294,790
New +$2.76M
ATNM icon
44
Actinium Pharmaceuticals
ATNM
$25.5M
$2.86M 0.84%
+271,588
New +$2.06M
ASLN
45
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$2.75M 0.8%
34,424
+2,051
+6% +$139K
AVTX icon
46
Avalo Therapeutics
AVTX
$955M
$2.6M 0.76%
+347
New +$2.52M
LSACU
47
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$2.31M 0.67%
210,000
– –
RDNT icon
48
RadNet
RDNT
$5.25B
$2.15M 0.63%
+135,254
New +$1.96M
ZYNE
49
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$2.12M 0.62%
+629,000
New +$2.97M
SYRE icon
50
Spyre Therapeutics
SYRE
$8.24B
$1.95M 0.57%
+8,444
New +$1.61M
1
2
3 4

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
WIC
Wilkins Investment Counsel Boston, Massachusetts $698M AUM 17.36% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return

Sio Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Sio Capital Management held 100 positions worth $343M, up 15% from $298M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Sio Capital Management withdrew a net $16.9M in Q2 2020, closing 22 positions and reducing 28 holdings. Its most notable exit was Amgen, an estimated $21.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 84% a quarter earlier, followed by Industrials and Financials.

Against the trend, Sio Capital Management opened a new position in Soliton, Inc. worth $7.97M.

  • Sio Capital Management's largest Q2 2020 buy was Soliton, Inc.: 1,025,000 shares worth $7.97M.
  • Sio Capital Management added most to SPDR Gold Trust in Q2 2020, an estimated $9.03M increase.
  • Sio Capital Management's biggest Q2 2020 reduction was Boston Scientific, cutting an estimated $10.2M.
  • Sio Capital Management fully exited Amgen in Q2 2020, selling an estimated $21.5M.
  • Sio Capital Management's ten largest holdings make up 37% of its $343M portfolio in Q2 2020.
  • Sio Capital Management opened 31 new positions and closed 22 in Q2 2020.
  • Sio Capital Management's portfolio value rose 15% quarter-over-quarter to $343M.

Based on Sio Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.